EVALUATING THE SIDE EFFECTS OF MATERNAL MAGNESIUM SULFATE RECEIVED IN PRE-ECLAMPSIA IN TERM AND LATE-TERM NEONATES IN 2015 AND 2016

Using magnesium sulfate might prevent the seizure, it could lead to poisoning in the patient. The present study aims at evaluating the side effects of maternal magnesium sulfate consumption in pre-eclampsia on term and late-preterm neonates.

This is a retrospective descriptive analytical study. One hundred term (group 1) and 100 late-preterm neonates (group 2) that were born in Shahid Motahari hospital of Urmia University of Medical Sciences from mothers with pre-eclampsia who had received magnesium sulfate, and as the control group, 100 neonates from mothers with pre-eclampsia who had not received magnesium sulfate (group 3) entered the study with easy and available sampling. 

The mean duration of sulfate uptake in the first group was 8.96±9.80 days and in the second group was 27.66±15.23 days and this difference was significant (p = 0.035). In the first group, 94 infants (94%), in the second group, 21 infants (21%), and in the third group, 64 infants (64%) did not need breathing support, which showed a significant difference between the groups (p <0.001). The first and fifth minute Apgar scores were significantly lower in the second group than in the first group and control, but this difference was not significant (p >0.05).

The findings of the present study depicted that magnesium sulfate administered for pre-eclampsia does not lead to neonates’ hypotonia, more admission days in the ward or NICU, and low Apgar scores.